[{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Intsel Chimos","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Intsel Chimos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intsel Chimos \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Intsel Chimos \/ Biophytis"},{"orgOrder":0,"company":"Seqens","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seqens \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Seqens \/ Biophytis"},{"orgOrder":0,"company":"Skyepharma","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Skyepharma \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Skyepharma \/ Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CER-001","moa":"APOA-I","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CER-001","moa":"APOA-I","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2025","type":"Funding","leadProduct":"CER-001","moa":"APOA-I","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Bpifrance","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Bpifrance"},{"orgOrder":0,"company":"Sanofi","sponsor":"DNDi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acoziborole","moa":"Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ DNDi","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ DNDi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.

                          Product Name : Sarconeos

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 25, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Biophytis

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Skyepharma Company Banner

                          02

                          Details : The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.

                          Product Name : Sarconeos

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 18, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Biophytis

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Seqens Company Banner

                          03

                          Details : Acoziborole, a potentially transformative investigational treatment for sleeping sickness, has a favourable safety profile, with no significant drug-related safety signals reported.

                          Product Name : SCYX-7158

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 30, 2022

                          Lead Product(s) : Acoziborole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : DNDi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Lead Product(s) : Sarilumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The US based trial will begin at medical centers in New York and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.

                          Product Name : Kevzara

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 16, 2020

                          Lead Product(s) : Sarilumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funding will be used for ABIONYX Pharma’s CER-001 Sepsis project. CER-001 is a negatively-charged lipoprotein particle which contains human recombinant apoA-I.

                          Product Name : CER-001

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          February 20, 2025

                          Lead Product(s) : CER-001

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Bpifrance

                          Deal Size : $9.1 million

                          Deal Type : Funding

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating severe forms of COVID-19.

                          Product Name : BIO101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Sarconeos (20-hydroxyecdysone) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating COVID-19.

                          Product Name : BIO101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 20, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The proceeds will fund research and development and clinical trials of its product canditates including, Sarconeos (BIO101), a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory ...

                          Product Name : BIO101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 19, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $3.8 million

                          Deal Type : Public Offering

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Sarconeos (BIO101, 20-hydroxyecdysone), is a small molecule, administered orally, a key component of the protective arm of the RAS, has shown positive results in the treatment of adult patients with a severe form of COVID-19.

                          Product Name : BIO101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 26, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Intsel Chimos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the terms of the agreement, Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug BIO101 (sarconeos) developed by Biophytis, requested for the treatment of severe forms of COVID-19, if...

                          Product Name : BIO101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 03, 2023

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Biophytis

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank